Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors

Table 6 Characteristics and outcome of canine patients treated with pump inhibitors and chemotherapy

PATIENT	AGE	TUMOR	PREV. TREATMENT	THERAPY	OUTCOME (MONTHS)
GREAT DANE	10	SPLENIC HSA	SURGERY METRONOMIC	METRONOMIC	CR 3
WHWT	8	LSA	MADISON MOPP	MOPP	CR 12
BULL MAST.	11	ALL	MADISON MOPP	MOPP	CR 3
WHWT	8	LSA	MADISON MOPP	MOPP	CR 8
ROTTW.	6	LSA	MADISON MOPP	MOPP	CR 3
BOXER	8	LSA	MADISON MOPP	MOPP	CR 7
BOXER	9	LSA	MADISON MOPP	MOPP	CR 5
DOGO	10	LSA	MADISON MOPP	MOPP	PR 3
WHWT	10	LSA	MADISON MOPP	MOPP	PD
BOXER	10	LSA	COP MOPP	MOPP	CR5+
LABRADOR	8	LSA	COP MOPP	MOPP	CR5+
BULL DOG	10	SKIN LSA	MADISON MOPP	MITOXANTRONE	CR5+
POODLE	12	LSA	COP MOPP	MOPP	DISCONTINUED
SETTER	14	ORAL SCC	MITOXANTRONE	MITOXANTRONE	DISCONTINUED
MIXED	11	NASAL CA	MITOXANTRONE	MITOXANTRONE	PR 3+
MIXED	10	OSA	BIOPSY	CLODRONATE	PR 7
MIXED	11	OSA	BIOPSY	CLODRONATE	PR 11
SCHNAUTZER	9	OSA	BIOPSY	CLODRONATE	DISCONTINUED
MIXED	15	TCC BLADDER	PIROXICAM	PIROXICAM	SD 7+
BEAGLE	12	TCC BLADDER	SURGERY MITOXANTRONE	MITOXANTRONE	CR 2+
ROTTWEILER	5	MELANOMA	SURGERY CARBOPLATIN	CARBOPLATIN	NED 5+
MIXED	10	MAMMARY CA	SURGERY MITOXANTRONE	MITOXANTRONE	NED 5+
MIXED	10	MAMMARY CA	CARBOPLATIN DOXORUBICIN	MITOXANTRONE	PR 9+
MIXED	11	FSA	SURGERY, ECT	MITOXANTRONE	NED 3+
MIXED	12	MAMMARY CA	SURGERY MITOXANTRONE	MITOXANTRONE	NED 4+
GERMAN	8	MAMMARY	SURGERY	MITOXANTRONE	NED 4+
SHEPHERD		CA	MITOXANTRONE
HUSKY	13	MAMMARY	SURGERY	MITOXANTRONE	NED 5+
		CA.SA	MITOXANTRONE

Abbreviations: ALL: acute lymphocytic leukemia; CA: carcinoma; CA.SA: carcinosarcoma; COP: cyclophosphamide, oncovin (vincristine), prednisone; ECT: electrochemotherapy; FSA: fibrosarcoma; HSA: hemangiosarcoma; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine), prednisone, procarbazine; OSA: osteosarcoma; SCC: squamous cell carcinoma, WHWT: west highland white terrier. +: still alive.
Drugs schedule: doxorubicin 30 mg/m² every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 300 mg/m² every 21 days, mitoxantrone 6 mg/m² every 21 days. For Madison and MOPP protocols see table 4 and 5

ISSN: 1479-5876